Suppr超能文献

接受全身淋巴照射治疗的肾移植受者的免疫学研究。

Immunological studies of renal allograft recipients treated with total lymphoid irradiation.

作者信息

Bachetoni A, Cinti P, Sallusto F, Poli L, Pretagostini R, Alfani D, Renna Molajoni E, Cortesini R

机构信息

Consiglio Nazionale delle Ricerche, Roma.

出版信息

Allergol Immunopathol (Madr). 1991 Mar-Apr;19(2):69-77.

PMID:1772107
Abstract

It is well known that highly sensitized patients and/or high responders, even under CsA therapy, constitute a risk category for transplantation. Based on this evidence, in 1982, our group initiates a pilot study using total lymphoid irradiation (TLI) as a pre-transplant modulator of patient's immuno-response. TLI has been employed in 30 uremic, non diabetic, patients. During this experience the first protocol, characterized by pre-transplant TLI greater than 2,000 rads (13 pts.) and post-transplant conventional therapy, was abandoned because of the severe TLI side effects. In the second protocol TLI dose never exceeded 2,000 rads and CsA was given, at initial dose of 7-12 mg/Kg/day according to CsA blood through levels. The immunological monitoring was performed during TLI treatment and in the postoperative clinical course by cell markers profile determination and functional assays. The data obtained have demonstrated that TLI treatment causes a prolonged depression in CD4 positive cells, a predominant recovery of T suppressor population, a pronounced impairment of T functions and a development of specific unresponsiveness to donor antigens. Furthermore the TLI plus CsA protocol, showing an additive effect which steadily decreases patient immunoreactivity, a lack of side effects and a stable long term graft function seems to be a more useful method for transplantation in high-risk or in strongly immunoreactive patients.

摘要

众所周知,即使在环孢素(CsA)治疗下,高敏患者和/或高反应者仍是移植的风险类别。基于这一证据,1982年,我们团队开展了一项试点研究,使用全身淋巴照射(TLI)作为移植前患者免疫反应的调节剂。TLI已应用于30例非糖尿病尿毒症患者。在此过程中,第一个方案(其特点是移植前TLI大于2000拉德(13例患者),移植后采用传统治疗)因TLI的严重副作用而被放弃。在第二个方案中,TLI剂量从未超过2000拉德,并根据环孢素血药浓度,以7 - 12毫克/千克/天的初始剂量给予环孢素。在TLI治疗期间以及术后临床过程中,通过细胞标志物谱测定和功能测定进行免疫监测。所获得的数据表明,TLI治疗导致CD4阳性细胞长期减少,T抑制细胞群占主导地位的恢复,T功能明显受损以及对供体抗原产生特异性无反应性。此外,TLI加环孢素方案显示出累加效应,能持续降低患者的免疫反应性,无副作用且移植功能长期稳定,似乎是一种更适用于高危或免疫反应强烈患者移植的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验